Company: CSCIF
Filing Date: 2025-06-02
Form Type: 6-K
Source: 0001641172-25-013138
Chunk: 1

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-06-02
Form: 6-K
Chunk 1
---
 | management’s assumptions,                                                                                                            
 estimates and judgements;                                                                                                            |
| ● | liquidity and capital resources;                                                                                                     |
| ● | adequacy of our financial                                                                                                            
 resources to finance operations and expenditure requirements;                                                                        |
| ● | limitations on internal                                                                                                              
 controls over financial reporting; and                                                                                               |
| ● | the plans, objectives,                                                                                                               
 future outlook and financial position of the Company in general.                                                                     |

Additional risk factors that could cause actual results to differ materially include those risks identified in Item 3. “Key Information – Risk Factors” contained in the Company’s most recent Annual Report on Form 20-F filed with the SEC and its other filings and submissions from time to time, including those containing its quarterly and annual results, with the SEC, which are available on the Company’s website located at www.cosciensbio.com.

Many of these risks and factors are beyond the Company’s control. The Company cautions you not to place undue reliance on these forward-looking statements. All written and oral forward-looking statements attributable to the Company or persons acting on their behalf, are qualified in their entirety by these cautionary statements. Moreover, unless required by law to update these statements, the Company will not necessarily update any of these statements after the date hereof, either to conform them to actual results or to changes in their expectation.

<div align='center'>DOCUMENTS INDEX</div>

| Exhibit |     | Description                                                             |
| 99.1    |     | COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders |

<div align='center'>SIGNATURE</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: May 30, 2025 | COSCIENS       
 Biopharma Inc. 
 By:            | /s/                     
 Giuliano La Fratta      |
|:-------------------|:---------------|:------------------------|
|                    |                | Giuliano La Fratta      |
|                    |                | Chief Financial Officer |